Haemophilic patients are at increased risk from hepatitis B virus infection because of their need for blood product therapy. They are potentially poor responders to hepatitis B vaccine due to immunological abnormalities resulting from two causes: infection with the human immunodeficiency virus and t
Prevalence of antibodies to hepatitis C virus (HCV) in haemophiliacs
✍ Scribed by Schramm, W. ;Roggendorf, M. ;Rommel, F. ;Kammerer, R. ;Pohlmann, H. ;Ra�hofer, R. ;G�rtler, L. ;Deinhardt, F.
- Publisher
- Springer-Verlag
- Year
- 1989
- Weight
- 259 KB
- Volume
- 59
- Category
- Article
- ISSN
- 1432-0584
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract The prevalence of antibody to hepatitis C virus (HCV) in a cohort of 272 HIV‐infected patients was assessed by means of 4 anti‐HCV assays: a 1st generation and a neutralization test, a 2nd generation test, and a confirmatory test, the dot‐blot Matrix HCV™ immunoassay. The cohort include
## Abstract Several studies had been carried out on anti‐hepatitis C virus (HCV) prevalence in populations with blood exposure risks and in blood donors. New tests are now available which allow the in‐ vestigation to extend to other parameters such as antibody type and HCV‐RNA. In this study the p
## Abstract The prevalence and the characteristics of hepatitis C virus infection (HCV) in 161 HIV‐positive patients were studied. HCV seroprevalence was determined by enzyme immunoassay and recombinant immunoblot assay (RIBA). Two different reverse transcriptase polymerase chain reaction (RT‐PCR)
## Abstract The prevalence of antibodies to hepatitis C virus (anti‐HCV) was studied in North East England in blood donors, local multiply transfused patients, local high risk individuals, and chronic liver disease patients. Anti‐HCV was detected by enzyme‐linked immunosorbent assay (ELISA) in 2/11
trast, only a minor proportion of HCV RNA posi-A small proportion of patients with chronic hepative patients, but anti-HCV seronegative by comtitis C virus (HCV) infection show no serological mercial immunoassays, have humoral immune responses to the HCV polypeptides incorporated responses to the HC